Knoll Considering Segard Plans; Sepsis Study Shows Small Mortality Benefit

Knoll is considering the next step for its TNF inhibitor Segard, after one of two pivotal trials for sepsis showed a modest mortality benefit.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet